Vertex Lifts Full-Year Revenue Forecast on Strong Cystic Fibrosis Drug Sales

Vertex Pharmaceuticals raised its full-year revenue forecast on Monday, citing robust demand for its portfolio of cystic fibrosis treatments. The updated guidance followed a second-quarter report where the biotech firm beat revenue expectations, propelled by the strong performance of its newer therapy.

Updated Guidance and Q2 Performance

Vertex now expects its annual revenue for 2026 to be between $13.1 billion and $13.2 billion. This is an increase from its previous forecast of $12.95 billion to $13.1 billion. The revised range positions the company's expectations slightly above the analyst consensus of $13.07 billion, according to LSEG data.

The forecast revision comes after the company reported a 12% year-over-year increase in second-quarter total revenue, which reached $3.33 billion and surpassed estimates of $3.23 billion. Vertex reported an adjusted profit of $4.73 per share, which was in line with analyst expectations.

Drug Sales Breakdown

The company's growth was largely driven by its new once-daily cystic fibrosis drug, Alyftrek. Sales for the therapy surged to $573.6 million during the second quarter, a substantial increase from the $156.8 million recorded in the same period a year ago.

Ad

However, sales for Trikafta, the company's older combination therapy for the same condition, posted quarterly sales of $2.50 billion. While a significant contributor to revenue, this figure fell short of analyst estimates of $2.65 billion.

Strategic Outlook

Vertex specified that its updated annual forecast does not include the financial impact of its pending $10 billion acquisition of Crinetics. The company stated it will provide a new forecast after the deal closes, which is anticipated in the third quarter.

For investors, the acquisition represents a key part of Vertex's strategy to diversify beyond its core cystic fibrosis franchise. The deal is set to expand the company's pipeline into endocrine disorders, complementing existing diversification efforts in kidney disease, sickle cell disease, and pain management.